ABL Diagnostics Société anonyme (EPA: ABLD)

Market Cap	40.28M
Revenue (ttm)	6.21M
Net Income (ttm)	184.66K
Shares Out	16.11M
EPS (ttm)	n/a
PE Ratio	218.16
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.500
Previous Close	2.500
Day's Range	2.500 - 2.500
52-Week Range	2.500 - 9.700
Beta	-0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 17, 2024

About EPA: ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and sali...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: Chalom Sayada
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABLD

Financial Performance

In 2023, ABLD's revenue was 6.19 million, a decrease of -33.89% compared to the previous year's 9.36 million. Earnings were 54,362, a decrease of -95.08%.